AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03146286 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish Oil
Description: Fish Oil, Omega 3 PUFA
Study NCT04558697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Shepherd's Purse extractum oleosum vagitories
Description: Shepherd's Purse extractum oleosum vagitories will be administered once daily for 5 days
Study NCT04558697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tea tree oil vagitories
Description: Tea tree oil vagitories will be administered once daily for 5 days
Study NCT04558697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperici extractum oleosum vagitories
Description: Hyperici extractum oleosum vagitories will be administered once daily for 5 days
Study NCT04558697 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vagitories - Probiotic
Description: Vagitories - Probiotic will be administered once daily for 5 days
Study NCT02582671 — intervention group
Intervention type: DRUG
Intervention: Ombitasvir/paritaprevir/ritonavir
Description: Co-formulated tablet
Study NCT02582671 — intervention group
Intervention type: DRUG
Intervention: Dasabuvir
Description: Tablet
Study NCT02582671 — intervention group
Intervention type: DRUG
Intervention: Ribavirin
Description: Tablet
Study NCT01276288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773
Description: multiple oral doses
Study NCT01276288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydrochlorothiazide
Description: multiple oral doses
Study NCT01276288 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: torasemide
Description: multiple oral doses
Study NCT01276288 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BI 10773
Description: multiple oral doses
Study NCT01276288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: torasemide
Description: multiple oral doses
Study NCT01276288 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hydrochlorothiazide
Description: multiple oral doses
Study NCT03377634 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MORPH
Description: Participants will engage in 12 weekly group coaching sessions discussion behavioral approaches to pain management, weight loss, and daily physical activity. The first three sessions (i.e., weeks 1 - 3) will occur in-person, and the remaining 9 will take place via telephone. All intervention participants will receive access to an activity monitor, smart scale, and smartphone app that aims to provide support for daily physical activity and weight loss.
Study NCT04028037 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FTPGT treated patients
Description: The recipient bed will be prepared according to Langer\&Langer modified technique. Intrasulcular incision will be performed from at least one tooth mesial and one tooth distal to the tooth with gingival recession, without vertical incisions.A split-thickness flap will be raised.The harvest of palatal graft will be done using FTPG technique. An incision, parallel to the gingival margin, deep to the bone, will be made. At the center of this incision, a U shaped one about 1-2mm deep will made, with the convex side towards the palatine vault.The width of the U incision will be equal to the width of the GR and the length will be 1mm greater.A split-thickness dissection of the area surrounding the U shaped incision will be done.The graft will be removed by detaching it from the bony surface.The graft will be made up of an apico-lateral portion of connective tissue and periosteum, and of a full-thickness central part.The palatal graft will be adapted to the recipient site and sutured.
Study NCT04028037 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CAF+SCTG treated patients
Description: According to De Sanctis \& Zucchelli, a tension-free trapezoidal flap will be elevated by the split-full-split technique and the anatomic papillae will be de-epithelialized. A 1-mm thick SCTG will be harvested from the palate as epithelialized graft. The height of the graft was equal to the distance between the buccal bone crest and the CEJ. After epithelium removal, the graft was positioned and sutured 1mm apical to the cement-enamel junction with 5-0 resorbable sutures . The SCTG will then be covered by the tension-free coronally positioned flap, sutured about 2mm over the CEJ by 5-0 silk sutures.
Study NCT03582111 — intervention group
Intervention type: OTHER
Intervention: Study of medical records
Description: Study of medical records
Study NCT01442025 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Infliximab
Description: Perfusion of IFX 5mg/kg to be increased to 10 mg/kg based on clinical symptoms
Study NCT01442025 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Infliximab
Description: Perfusion of IFX 5mg/kg or 10 mg/kg if dose increase criteria are met (biological)
Study NCT01442025 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Infliximab
Description: Perfusion of IFX 5mg/kg or 7,5 mg/kg if dose increase criteria are met (biological)and 10mg/kg if dose increase criteria are met for a second time
Study NCT04237493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin and Glimepiride (Low Dosage)
Description: * Metformin (PO; 850 mg; BID \[with Ifṭār and with Suḥūr\])~* Glimepiride (PO; 1.5 or 3 mg \[75% of the pre-Ramadan dose\]; OD \[with Ifṭār\])
Study NCT04237493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin and Vildagliptin (Low Dosage)
Description: * Metformin (PO; 850 mg; BID \[with Ifṭār and with Suḥūr\])~* Vildagliptin (PO; 50 mg; OD \[with Ifṭār\])
Study NCT04237493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin and Insulin Glargine U100 (Low Dosage)
Description: * Metformin (PO; 850 mg; BID \[with Ifṭār and with Suḥūr\])~* Insulin Glargine U100 (SC; 9-33 units \[75% of the pre-Ramadan dose\]; OD \[at 10 P.M.\])
Study NCT04237493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin, Insulin Glargine U100, and Human Regular Insulin (Low Dosage)
Description: * Metformin (PO; 850 mg; BID \[with Ifṭār and with Suḥūr\])~* Insulin Glargine U100 (SC; 6-39 units (75% of the pre-Ramadan dose); OD \[at 10 P.M.\])~* Human Regular Insulin (SC; 15-33 units before Ifṭār and 6-18 units before Suḥūr \[75% of the pre-Ramadan doses\])
Study NCT04237493 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin and Glimepiride (Regular Dosage)
Description: * Metformin (PO; 850 mg; BID \[with Ifṭār and with Suḥūr\])~* Glimepiride (PO; 2 or 4 mg \[100% of the pre-Ramadan dose\]; OD \[with Ifṭār\])
Study NCT04237493 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin and Vildagliptin (Regular Dosage)
Description: * Metformin (PO; 850 mg; BID \[with Ifṭār and with Suḥūr\])~* Vildagliptin (PO; 50 mg; BID \[with Ifṭār and with Suḥūr\]\])
Study NCT04237493 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin and Insulin Glargine U100 (Regular Dosage)
Description: * Metformin (PO; 850 mg; BID \[with Ifṭār and with Suḥūr\])~* Insulin Glargine U100 (SC; 11-44 units \[100% of the pre-Ramadan dose\]; OD \[at 10 P.M.\])
Study NCT04237493 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin, Insulin Glargine U100, and Human Regular Insulin (Regular Dosage)
Description: * Metformin (PO; 850 mg; BID \[with Ifṭār and with Suḥūr\])~* Insulin Glargine U100 (SC; 8-52 units (100% of the pre-Ramadan dose); OD \[at 10 P.M.\])~* Human Regular Insulin (SC; 12-40 units before Ifṭār and 7-28 units before Suḥūr \[100% of the pre-Ramadan doses\])
Study NCT02536586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3023414
Description: LY3023414 administered orally.
Study NCT01696812 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: electrode position
Study NCT04036825 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Liquid Nutritional Supplement from Hospital Product
Description: Liquid Nutritional Supplement from Hospital Product is given 2 times daily for 14 days
Study NCT04036825 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Standard nutritional supplement is given 2 times daily as placebo for 14 days
Study NCT03435978 — intervention group
Intervention type: BEHAVIORAL
Intervention: MetS+
Study NCT03435978 — intervention group
Intervention type: OTHER
Intervention: MetS-
Description: Data processing from Patient Medical Files
Study NCT04525703 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pathways for Parents after Incarceration
Description: The Pathways for Parents after Incarceration program uses eight key lessons, including topics on effective listening, speaking, and problem-solving skills, lessons on emotion regulation, and issues surrounding family engagement. The program (both classroom and therapeutic peer support) will be offered virtually and weekly for 8 continuous weeks.
Study NCT04626830 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile Application Intervention
Description: Participants appointed to the intervention group will receive the mobile application intervention for six months after enrollment. The mobile app (OKTED) intervention will consist of completing responding to weekly assessments regarding symptoms, side effects, and medication adherence, as well as receiving personalized feedback about responses.
Study NCT01274221 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SPD489
Description: 1 capsule per day throughout the open-label treatment phase and for one week of the double-blind crossover phase
Study NCT01274221 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 capsule per day for one week of the double-blind crossover phase
Study NCT01496664 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Combined CABG and PCI
Description: Coronary artery bypass grafting Percutaneous coronary intervention
Study NCT03519048 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nasofibroscopy
Description: every 1-3 months first year post-treatment, every 2-4 months second year, every 4-6 months third year (mean of around 13 visits) and every 6 months thereafter
Study NCT03519048 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low Dose Chest CTscan
Description: every year in patients with tobacco consumption history of > 20 pack-year
Study NCT03519048 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: injected CT-scan
Description: the first performed 12 months after inclusion
Study NCT03519048 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: whole body PET-CT
Description: annual whole body PET-CT (the first at 6 months after inclusion)
Study NCT03519048 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lugol upper gastrointestinal endoscopy
Description: the first performed 12 months after inclusion
Study NCT03519048 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biopsy
Description: In both arm, patient will have a confirmation biopsy in case of suspicion of relapse or second primary.
Study NCT03519048 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: In both arm, patient will have a confirmation biopsy in case of suspicion of relapse or second primary.
Study NCT02109237 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Assessment of sleep disorders and treatment if required
Description: Assessment of sleep disorders and treatment if required
Study NCT02109237 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Assessment of sleep disorders and treatment if required
Description: Assessment of sleep disorders and treatment if required
Study NCT02886429 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Ultrasound guided paravertebral block with bupivacaine
Study NCT02886429 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Ultrasound guided paravertebral block with dexmedetomidine
Study NCT00783627 — intervention group
Intervention type: PROCEDURE
Intervention: Angiography
Description: Angiography done at the J1 visit
Study NCT00840632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trandolapril 4 mg Tablets
Description: 1 x 4 mg, single-dose fasting
Study NCT00840632 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mavik® 4 mg Tablets
Description: 1 x 4 mg, single-dose fasting
Study NCT01334307 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lung Volume Reduction Coil (LVRC) (PneumRx)
Description: Lung Volume Reduction Coil (LVRC)
Study NCT01886560 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets placebo one PO per day for 12 weeks
Study NCT02538198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Study NCT02300480 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CTB group
Description: CTB: A single injection of 1.0% 10ml ropivacaine by bile duct needle in calot's triangle when before surgical dissection.After surgery,participants in this group will also receive PCIA.
Study NCT02300480 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PCIA group
Description: The formula of the PCIA included tramadol 800 mg, flurbiprofen axetil 100mg with saline added up to a volume of 80 ml in total. The PCIA pump was set up with a 5 ml loading dose, a 2 ml bolus dose, a 15 min lockout interval and background infusion at a rate of 1 ml/h.
Study NCT04376697 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS)
Description: The treatment will be delivered by trained medical personnel.
Study NCT01280240 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Monofer(R)
Description: Intravenous bolus injection given over app. 2 minutes only once
Study NCT01334307 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Standard of Care
Study NCT00249496 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency management
Description: Participants in the Contingency Management group will be employed for one year in a Therapeutic Workplace business and will have to provide drug-free urine samples to work and earn salary.
Study NCT00249496 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Employment Only
Description: Employment Only participants will be offered employment for one year, but these participants will not have to provide drug-free urine samples to work.
Study NCT04215393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conbercept eye drop
Description: In the first stage, subjects will be receive Conbercept eye drop. In the second stage,subjests will revceive conbercept eye drop or placebo.
Study NCT04215393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: In the second stage, subjects will be receive Conbercept eys drop or a placebo.
Study NCT02605382 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate
Study NCT02605382 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Solution chemical manufactured to mimic 0.12% chlorhexidine mouthwash
Study NCT02293174 — intervention group
Intervention type: DEVICE
Intervention: Topcon TRC-NW400
Description: Retinal Fundus Camera
Study NCT02293174 — intervention group
Intervention type: DEVICE
Intervention: TRC-NW8
Description: Retinal Fundus Camera
Study NCT02293174 — intervention group
Intervention type: DEVICE
Intervention: TRC-NW400
Description: Retinal Fundus Camera
Study NCT02293174 — intervention group
Intervention type: DEVICE
Intervention: Canon-CR2
Description: Retinal Fundus Camera
Study NCT02293174 — intervention group
Intervention type: DEVICE
Intervention: Zeiss Visucam PRO
Description: Retinal Fundus Camera
Study NCT04227860 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Balance exercise program
Description: Patients will be engaged in lower extremity kinesthesia and balance exercise program 3 time per week for 6 weeks.~Divided into 2 stages, stage 1 and 2, each stage 3 weeks. Patients who fulfill at least stage 1 of the program will be included in the study.
Study NCT00467896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iloprost PD-6
Description: Period I: Patients received iloprost administered using PD-6 for the 37 days prior to the first dosing of iloprost using PD-15. Iloprost inhalation solution was delivered using the I-neb® AAD System. Patients were required to use their own I-neb®.
Study NCT00467896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iloprost PD-15
Description: Period II: Iloprost inhalation solution was delivered using the investigational product PD-15 with I-neb® AAD System for 37 days. Patients were required to use their own I-neb®.
Study NCT03548519 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: OCAT-only
Description: online-contingent Attention Training without prior psychoeducation
Study NCT03548519 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: OCAT-sham
Description: Placebo version of Online contingent Attention Training without prior psychoeducation
Study NCT03548519 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: OCAT-combo
Description: Online contingent Attention Training with prior psychoeducation
Study NCT01027923 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plerixafor
Study NCT04227860 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Strengthening exercise program
Description: Patients will be engaged in strengthening exercise program 3 time per week for 6 weeks.~Divided into 3 stages, stage 1, 2 and 3, each stage 2 weeks. Patients who fulfill at least stage 1 of the program will be included in the study.
Study NCT01027923 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Study NCT00077350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: triapine
Description: Given IV
Study NCT00077350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IV
Study NCT00077350 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01481025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cimicifuga + Hiperico
Description: 1 tablet, 80+450mg/tablet, twice a day for 1-3 months~1 tablet, 80+450mg/tablet, once a day for 3-6 months
Study NCT01481025 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cimicifuga Herbarium
Description: 2 caps, 80mg/caps, once a day for 1-3 months~1 caps, 80mg/caps, once a day for 3-6 months
Study NCT01481025 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aplause®
Description: 4 tablets, 20mg/tablet, twice a day for 1-3 months 2 tablets, 20mg/tablet, twice a day for 3-6 months
Study NCT03743818 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: dry needling
Description: dry needling on the trigger point of the vastus medialis of the quadriceps
Study NCT01027923 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Study NCT01027923 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Study NCT02975622 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Central venous catheterization
Description: Ultrasound guided central venous catheterization
Study NCT00420303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: 50 mg injection once weekly
Study NCT00420303 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study NCT01394497 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcystein
Description: 15 min systemic NAC infusion of the donor (30 mg/kg, maximum dose 3000 mg) diluted into 500 ml 5 % glucose solution, 30 min before initiating the liver harvesting procedure, and a loco-regional infusion (150 mg/kg of estimated liver weight, maximum dose 300 mg) into the portal vein 5 min before cross-clamping.
Study NCT03743818 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound
Description: aply ultrasound on the knee
Study NCT03743818 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: hyauluronic acid
Description: aply hyaluronic acid on the knee
Study NCT04676230 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Experimental group
Description: Caries management based on the ICCMSTM: Patient intervention according to the caries risk likelihood: high, moderate or low. Surfaces intervention according to the surface diagnosis decision matrix (ICCMSTM): Mi: Initial caries management, Mm: Moderate caries management, and Me: Extensive caries management.
Study NCT04676230 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Systematic patient caries risk intervention (all managed as high risk patients). Surfaces intervention with conventional caries management of cavitated/dentin caries lesions (restorative treatment).
Study NCT03544411 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: olive oil
Description: the intervention consist of 15 ml / day of olive oil
Study NCT02813460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation A (ALS-008176)
Description: Reference formulation, 60 mg/mL ALS-008176 oral suspension without sweetener/flavor.
Study NCT03544411 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bran oil
Description: the intervention consist of 15 ml / day of bran oil
Study NCT04587570 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Infiltration with PRP
Description: Infiltration with 1.5 ml PRP